Provided By GlobeNewswire
Last update: Jul 16, 2025
BOSTON, July 16, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, today provided a clinical update on its most advanced asset, CUE-101, representative of the CUE-100 series.
Read more at globenewswire.com0.7372
-0.01 (-1.79%)
Find more stocks in the Stock Screener